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Abstract
Background: Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-
generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of
the central nervous system, including patients previously diagnosed with multiple sclerosis (MS). However, only limited
data are available on the relevance of MOG-IgG testing in patients with chronic progressive demyelinating disease. It is
unclear if patients with primary progressive MS (PPMS) or secondary progressive MS (SPMS) should routinely be tested
for MOG-IgG.
Objective: To evaluate the frequency of MOG-IgG among patients classified as having PPMS or SPMS based on current
diagnostic criteria.
Methods: For this purpose, we retrospectively tested serum samples of 200 patients with PPMS or SPMS for MOG-IgG
using cell-based assays. In addition, we performed a review of the entire English language literature on MOG-IgG published
between 2011 and 2017.
Results: None of 139 PPMS and 61 SPMS patients tested was positive for MOG-IgG. Based on a review of the literature, we
identified 35 further MOG-IgG tests in patients with PPMS and 55 in patients with SPMS; the only reportedly positive
sample was positive just at threshold level and was tested in a non-IgG-specific assay. In total, a single borderline positive
result was observed among 290 tests.
Conclusion: Our data suggest that MOG-IgG is absent or extremely rare among patients with PPMS or SPMS. Routine
screening of patients with typical PPMS/SPMS for MOG-IgG seems not to be justified.
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Background
Antibodies to human full-length myelin oligodendrocyte
glycoprotein (MOG-IgG) as detected by cell-based assays
have recently been implicated in the pathogenesis of central
nervous system (CNS) demyelination [1]. Most adult
MOG-IgG-positive patients present with optic neuritis
(ON), myelitis or brainstem encephalitis, though supraten-
torial brain lesions and epileptic seizures may occur as well
[2–9]. In addition, MOG-IgG has been demonstrated in
(mostly paediatric) patients with acute disseminated
encephalomyelitis. MOG-IgG-related encephalomyelitis
(MOG-EM) is now considered by many experts a disease
entity in its own right, pathogenetically distinct from both
classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-
IgG-positive neuromyelitis optic spectrum disorders [10].
So far, MOG-IgG has been almost exclusively reported in
patients with monophasic or relapsing-remitting acute dis-
ease. However, as a major limitation, many previous studies
had explicitly excluded patients with chronic progressive
demyelination. It is therefore possible that MOG-IgG has
so far been overlooked in patients with chronic progressive
MS. To obtain more definite data on the role of MOG-IgG
in chronic progressive CNS demyelination, we decided to
test a large cohort of patients previously diagnosed with
primary progressive MS (PPMS) or secondary progressive
MS (SPMS) for MOG-IgG.
Methods
Serum samples from 200 patients with chronic progressive
MS according to the 2010 McDonald criteria, comprising
139 with PPMS and 61 with SPMS, were retrospectively
tested for MOG-IgG. Human embryonic kidney (HEK) 293
cells transfected with full-length human MOG were used
as antigenic substrate in combination with control cells as
previously described [4, 11]. Samples yielding both a titer of
≥ 1:10 in the fixed cell-based assay and a titer of ≥ 1:160 in
the live cell-based assay were considered positive [4, 11].
The sex ratio was 1:1.2 (female to male) in the total cohort,
1:1.9 in the PPMS subgroup, and 1:0.36 in the SPMS sub-
group. The median age at the time of testing was 48 years
(range 18–77) in the total cohort, 51 (31–77) among
patients with PPMS, and 47 (22–74) among patients with
SPMS. The median expanded disability status scale (EDSS)
score was 4.5 (range 1.5–9) in the total cohort, 4 (1.5–9)
among patients with PPMS, and 6.5 (2–9) among patients
with SPMS. The median disease duration at the time of
blood sampling was 7.9 years (range 1–50.7) in the total
cohort, 6 (range 1–36) in the PPMS subgroup, and 17
(range 1–50.7) in the SPMS subgroup. Data on treatment
at the time of blood sampling were available from 188/200
(98%) patients; most patients (151/188 or 80.3%) were not
treated with immunosuppressive drugs or steroids at the
time of sampling. The study was approved by the institu-
tional review boards of the participating centers. The
patients gave written informed consent or were tested in an
anonymised fashion as required by the institutional review
board of the University of Heidelberg. Samples were stored
at − 80 °C prior to testing. Sixteen MOG-IgG-positive
serum samples from previously reported patients with ON
and/or myelitis were used as positive controls [2–5],
including 13 samples that had previously yielded low-titer
results in the live-cell assay (1:160–1:320). In addition, we
performed a review of the entire literature on MOG-IgG
published in English in journals indexed in the PubMed
database of the US Library of Science at the US National
Institutes of Health between 2011 and 2017.
Results
None of 200 patients with primary (N = 139) or secondary
(N = 61) chronic progressive MS was positive for MOG-
IgG. All positive controls were correctly detected. Based
on a review of the English language literature, 35
additional tests for MOG-IgG in patients with PPMS and
55 in patients with SPMS were identified (Table 1). The
only reportedly MOG-IgG-positive case we could identify
in the literature—a patient previously diagnosed with
SPMS—was positive just at threshold level when tested in
a semiquantitative assay [11]. Considering the 200 patients
tested in the present study and the 90 reported in the
previous literature, MOG-IgG has been detected in 0/174
patients with PPMS and in 1/116 patients with SPMS,
with the only reportedly positive sample having yielded a
borderline result (Table 1). Moreover, the latter sample
was positive in a semiquantitative assay employing a non-
Table 1 MOG-IgG in patients with PPMS and SPMS as found in the present study and as reported in the literature
PPMS SPMS
Jarius et al., present study 139, none positive for MOG-IgG 61, none positive for MOG-IgG
Jarius et al., J Neuroinflammation 2016 [4] 5, none positive for MOG-IgG 11, none positive for MOG-IgG
Martinez-Hernandez et al., JAMA Neurol 2015 [16] 10, none positive for MOG-IgG 9, none positive for MOG-IgG
Höftberger et al., Mult Scler 2015 [17] 10, none positive for MOG-IgG 10, none positive for MOG-IgG
Mader et al., J Neuroinflammation 2011 [11] 8, none positive for MOG-IgG 19, one borderline positive for MOG-IgG (1:160)
Ramanathan et al., Neurol Neuroimmunol Neuroinflamm 2014 [18] 2, none positive for MOG-IgG 6, none positive for MOG-IgG
Total 0/174 1/116 (borderline result)
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Fc specific secondary anti-IgG antibody recognizing both
heavy and light chains, leaving the possibility that the patient
was in fact positive for MOG-IgM antibodies of unclear
diagnostic relevance rather than MOG-IgG antibodies.
Discussion
Given the potential prognostic and therapeutic conse-
quences of a chronic progressive disease course, addressing
the question of whether MOG-IgG can be associated with
chronic progressive demyelination is of high clinical rele-
vance. Our data indicate that MOG-IgG is present only
extremely rarely or not at all in adult patients diagnosed
with PPMS or SPMS (one borderline result among 290
tests [0.3%]; see Table 1 for details).
The very low frequency of MOG-IgG among patients
diagnosed with PPMS/SPMS on the one hand and the
lack of standardized assays for MOG-IgG testing and the
limited specificity of immunoassays in general on the
other hand bears the significant risk of an unfavourable
ratio of false-positive to true-positive results (a risk
generally attached to screening of large cohorts for very
rare markers [12, 13]). Based on the 0–0.3% positivity
rate among PPMS/SPMS patients observed in this study,
the number of false-positive results might even outnumber
the number of true-positive results if all PPMS/SPMS
patients were to be tested for MOG-IgG and assay specifi-
city were to be less than 99.7–100%. Therefore, we advise
against routine screening for MOG-IgG in patients with
PPMS or SPMS. Instead, we recommend limiting MOG-
IgG testing in patients with PPMS or SPMS to those with
clinical and/or paraclinical findings considered suggestive
of MOG-IgG-related encephalomyelitis, including, for ex-
ample, predominant attacks of ON or myelitis, longitudin-
ally extensive optic nerve or myelitis lesions, typical brain
magnetic resonance imaging (e.g. normal supratentorial
MRI; or no Dawson finger lesion, no juxtacortical U fibre
lesion, no ovoid/round lesion adjacent to a lateral ventricle,
and no lesion in the temporal lobe), or cerebrospinal
fluid findings that are atypical for MS (e.g. negative oligo-
clonal bands, neutrophilic pleocytosis, or white cell count
>50/µl) [2, 3, 14]. Finally, given that a progressive disease
course seems to be rare in MOG-EM [3] and thus atypical,
confirming a positive test result in patients with PPMS/
SPMS using a second, methodologically independent assay
or, if that is not possible, by testing of follow-up samples
(ideally taken during acute relapse [3] and/or during
treatment-free intervals) is advisable.
Finally, it should be taken into account that it can be
difficult in clinical practice to distinguish between a sec-
ondary chronic progressive disease course and disability
progression resulting from protracted attacks with incom-
plete remission or from mild attacks, some of which may
be just below the patient’s threshold of attention. In case
of doubt, MOG-IgG testing may therefore also be justified
in selected patients with suspected chronic progressive
disease, especially if the findings are otherwise suggestive
of MOG-EM. However, confirmation of a positive result
should be sought as outlined above.
We recognize that our study has potential limitations:
First, all of our patients were adults. While to the best of
our knowledge no paediatric patients with a progressive
course and confirmed MOG-IgG-positive serostatus have
yet been reported, further studies are certainly needed be-
fore any recommendations regarding MOG-IgG testing in
children with chronic progressive CNS demyelinating dis-
ease can be made. Second, we report data from a Euro-
pean cohort; to formally rule out that genetic factors play
a role, testing of other, e.g. Asian, populations seems advis-
able due to potential genetic differences. Third, treatment
effects may influence antibody titers. However, the vast ma-
jority of patients analysed here were not treated with im-
munosuppressive drugs at the time of blood sampling, and
MOG-IgG was also absent in all 151 patients not treated
with immunosuppressants or steroids. Fourth, assessing
disease activity in progressive MS according to current rec-
ommendations [15] requires monitoring of MRI activity
over time, since relapses are typically rare or missing. As
standardized MRI data were not available for the present
cohort, we cannot formally exclude a potential effect of dis-
ease activity. However, it is likely that disease activity in our
cohort was at least similar to that in the general PPMS/
SPMS population, since unselected, consecutive patients
were tested and since the sample size was high. Given that
all patients were recruited at tertiary centers and that pa-
tients with inactive, stable disease are less likely to be seen
at tertiary centers, disease activity may have been even
higher than in the general PPMS/SPMS population. On
the other hand, we count the multicenter design, which
helped to lower the risk of selection bias, the additional lit-
erature review, and the very large number of patients
tested among the strengths of this study.
Conclusion
In summary, our results argue against a major role of
MOG-IgG in patients with primary or secondary progres-
sive demyelination and may prove useful for future recom-
mendations on clinical indications for MOG-IgG testing.
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